Proteomics International Laboratories Ltd (ASX:PIQ) is pleased to announce it has appointed additional members to its Clinical Advisory Board adding world leading healthcare professionals from the United States.
ASX-listed Proteomics International Laboratories has beefed up its clinical advisory board ahead of the rollout of its Promarker D predictive test for diabetic kidney disease in type 2 diabetes patients.
Despite advances in diabetes care, hypoglycemia remains a common complication. Yes, new therapies are associated with less hypoglycemia risk, and patients are increasingly using continuous glucose monitoring, but episodes of hypoglycemia still occur. Some of these episodes are severe, and patients require assistance for recovery.
Despite advances in diabetes care, hypoglycemia remains a common complication. Yes, new therapies are associated with less hypoglycemia risk, and patients are increasingly using continuous glucose monitoring, but episodes of hypoglycemia still occur. Some of these episodes are severe, and patients require assistance for recovery.